微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 27.37% | -11.55% | -0.42% | 120/159 | -2.82% | 海创药业 | 99.57% | 行业排名> |
| 2025-06-30 | 27.49% | -9.5% | 5.17% | 124/159 | 15.28% | 海创药业 | 99.52% | 行业排名> |
| 2025-03-31 | 26.14% | -12.51% | -5.04% | 123/159 | 32.3% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 27.52% | 34.76% | -11.05% | 126/159 | 51.78% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 30.94% | 26.38% | 1.88% | 118/159 | 22.81% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 30.37% | 20.48% | 1.67% | 118/159 | 33.25% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 29.87% | 31.84% | 46.26% | 119/159 | 51.56% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 20.42% | -8.08% | -16.58% | 139/159 | 51.39% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 24.48% | 6.1% | -2.88% | 132/159 | 32.56% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 25.21% | 1.94% | 11.25% | 129/159 | 38.45% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 22.66% | -11.12% | 1.97% | 129/159 | 52.78% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 22.22% | -4.8% | -3.71% | 139/159 | 53.66% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 23.08% | -24.68% | -6.69% | 130/159 | 6.2% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 24.73% | -34.08% | -3% | 135/159 | 21.37% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 25.49% | -31.64% | 9.23% | 124/159 | 54.28% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 23.34% | 2.46% | -23.81% | 138/159 | 55.1% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 30.64% | 43.49% | -18.33% | 114/159 | 46.78% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 37.51% | 73.43% | 0.59% | 108/159 | 47.23% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 37.29% | 57.2% | 63.7% | 91/159 | 53.99% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 22.78% | -12.09% | 6.69% | 134/159 | -145.9% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 21.35% | -21.25% | -1.28% | 113/159 | 56.36% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 21.63% | -23.53% | -8.83% | 122/159 | 54.11% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 23.72% | -19.9% | -8.45% | 102/159 | 55.23% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 25.91% | -27.38% | -4.42% | 124/159 | -1222.98% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 27.11% | -37.12% | -4.15% | 97/159 | 55.21% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 28.29% | -41.3% | -4.5% | 104/159 | 55.21% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 29.62% | -37.51% | -16.99% | 94/159 | 51.05% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 35.68% | -3.62% | -17.25% | 102/159 | -208.09% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 43.12% | 15.97% | -10.53% | 67/159 | 53.97% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 48.19% | 29.29% | 1.68% | 60/159 | 53.39% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 47.4% | 25.74% | 28.02% | 60/159 | 53.9% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 37.02% | -14.95% | -0.42% | 85/159 | 52.32% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 37.18% | -26.34% | -0.25% | 66/159 | 49% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 37.27% | -27.69% | -1.12% | 71/159 | 47.74% | 贝达药业 | 95.81% | 行业排名> |
| 2017-03-31 | 37.69% | -14.92% | -13.41% | 56/159 | 46.55% | 退市金泰 | 95.93% | 行业排名> |
| 2016-12-31 | 43.53% | -14.8% | -13.75% | 60/159 | 48.19% | 贝达药业 | 95.58% | 行业排名> |
| 2016-09-30 | 50.47% | -5.38% | -2.09% | 31/159 | 45.76% | 贝达药业 | 95.89% | 行业排名> |
| 2016-06-30 | 51.55% | -8.83% | 16.35% | 34/159 | 45.89% | 微芯生物 | 97.46% | 行业排名> |
| 2016-03-31 | 44.3% | -10.89% | -13.28% | 35/159 | 43.5% | 贝达药业 | 97.01% | 行业排名> |
| 2015-12-31 | 51.09% | 20.46% | -4.22% | 40/159 | 45.97% | 贝达药业 | 97.02% | 行业排名> |
| 2015-09-30 | 53.34% | 39.78% | -5.66% | 23/159 | 44.69% | 舒泰神 | 94.38% | 行业排名> |
| 2015-06-30 | 56.54% | 58.41% | 13.73% | 24/159 | 45% | 贝达药业 | 96.95% | 行业排名> |
| 2015-03-31 | 49.72% | 56.88% | 17.22% | 29/159 | 43.46% | 舒泰神 | 94.4% | 行业排名> |